IYIA Launches Technology To Reduce Amputations Due To Diabetic Foot Ulcers
Chicago, IL - Everyday, someone someplace will have their lower limb amputated due to continual complications from a diabetic foot ulcer. Approximately 2.4 million diabetic foot ulcers are diagnosed each year in the U.S., many progressing to lower limb amputation. It is estimated that the U.S. healthcare costs for treating diabetic foot ulcers and related amputations exceed $10 billion per year.
IYIA Technologies Inc., San Marcos, CA, announced the launch recently at the American Diabetes Association annual meeting, their medical device, O2Misly, for the treatment of slow healing diabetic foot ulcers. The O2Misly device offers a combination, adjunctive therapy to the standard of care in the treatment of non-healing ulcers. O2Misly provides oxygen infused under tension in a closed chamber blended with a mist, which also delivers an antimicrobial to the affected area. This therapy can be conveniently delivered in a clinician's office and does not require the patient to be enclosed in a pressurized tube, as with total hyperbaric oxygen therapy. The O2Misly office based therapy will be a lot less expensive compared to the hospital based hyperbaric chamber treatment.
IYIA has conducted a clinical trial over the last 18 months and the results have been dramatic. Patients in the study had to have failed previous standard of care therapy before they could be included in the trial. 75.5% of the patients treated with O2Misly were healed within 12 weeks. 100% of the patients treated 20 weeks with O2Misly were healed.
Clark Adams, Chairman, IYIA Technologies, stated, "It is unfortunate that the medical device industry has taken so long to develop a cost- and clinically-effective system to treat and heal diabetic foot ulcers, which could reduce lower limb amputations. IYIA is proud to launch a system to help these patients to not only improve their quality of life but maintain their mobility as well."
SOURCE: IYIA Technologies Inc.